title: Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda.
abstract: Triple nucleoside reverse transcriptase inhibitors are recommended as an alternative regimen for HIV-infected patients undergoing tuberculosis treatment in resource-limited settings. Few data exist on the efficacy of such regimens in tuberculosis patients. In 34 tuberculosis/HIV-co-infected patients treated with zidovudine/lamivudine/abacavir, 76% achieved HIV RNA less than 50 copies/ml at 24 weeks. No cases of hypersensitivity or immune reconstitution syndrome were observed. These data support the continuing evaluation of nucleoside-based antiretroviral regimens as an alternative treatment for this population.
authors.affiliation: HIV/AIDS Division, San Francisco General Hospital, University of California, San Francisco, California, USA.
authors.forename: Padmini
authors.initials: P
authors.lastname: Srikantiah
authors.forename: Maria N
authors.initials: MN
authors.lastname: Walusimbi
authors.forename: H Kose
authors.initials: HK
authors.lastname: Kayanja
authors.forename: Harriet
authors.initials: H
authors.lastname: Mayanja-Kizza
authors.forename: Roy D
authors.initials: RD
authors.lastname: Mugerwa
authors.forename: Royce
authors.initials: R
authors.lastname: Lin
authors.forename: Edwin D
authors.initials: ED
authors.lastname: Charlebois
authors.forename: W Henry
authors.initials: WH
authors.lastname: Boom
authors.forename: Christopher C
authors.initials: CC
authors.lastname: Whalen
authors.forename: Diane V
authors.initials: DV
authors.lastname: Havlir
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D015224:Dideoxynucleosides / Q000009:adverse effects / Q000627:therapeutic use*; D004342:Drug Hypersensitivity / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D012367:RNA, Viral / Q000032:analysis; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D015215:Zidovudine / Q000009:adverse effects / Q000627:therapeutic use*; D000099227:Abacavir
chemical_list: D000995:Antitubercular Agents; D015224:Dideoxynucleosides; D019259:Lamivudine; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D000099227:Abacavir